Core One Labs Inc.: Core One Labs' Akome Achieves Significan

Opening the Door to Expanded Patent CoverageVANCOUVER, BC / ACCESSWIRE / August 18, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), further

Related Keywords

Canada , Vancouver , British Columbia , Canadian , Josea Morales Garcia , Luniversidad Complutense , Joel Shacker , Biomedical Research On Neurodegenerative Diseases , Cellular Biology Department , Autonoma University Of Madrid , Biosciences Inc , Core One Labs Inc , Akome Biotech Ltd , Vocan Biotechnologies Inc , Health Canada , Canadian Securities Exchange , Company Or Core , Master Of Pharmacological Research , Expanded Patent , Akome Biotech , Universidad Complutense De Madrid , Assistant Professor , Medical School , Networked Biomedical Research , Neurodegenerative Diseases , Pharmacological Research , Autonoma University , Core One , One Labs , Awakened Biosciences Inc , Disclaimer Statement , Controlled Drugs , Substances Act , Core One Labs , Core , Labs , Okome , Chieves , Significant , Research , Milestone , Positive , Neurogenesis , Stimulation , Studies , Results ,